An Orthotopic Mouse Model of Ovarian Cancer using Human Stroma to Promote Metastasis

10.3791/62382 ◽  
2021 ◽  
Author(s):  
Huda I. Atiya ◽  
Taylor J. Orellana ◽  
Alyssa Wield ◽  
Leonard Frisbie ◽  
Lan G. Coffman
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Orthotopic Mouse Model

scholarly journals An Immunocompetent, Orthotopic Mouse Model of Epithelial Ovarian Cancer Utilizing Tissue Engineered Tumor Cell Sheets

2015 ◽  
Vol 21 (1) ◽  
pp. 23-34 ◽  
Author(s):  
Ayumi Arauchi ◽  
Chieh-Hsiang Yang ◽  
Sungpil Cho ◽  
Elke A. Jarboe ◽  
C. Matthew Peterson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Tumor Cell ◽  
Epithelial Ovarian Cancer ◽  
Cell Sheets ◽  
Orthotopic Mouse Model

scholarly journals Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer

2014 ◽  
Vol 25 (2) ◽  
pp. 130 ◽  
Author(s):  
Ho-Suap Hahn ◽  
Ki-Heon Lee ◽  
In-Ho Lee ◽  
Jae-Ho Lee ◽  
Chang-Sung Whang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Orthotopic Mouse Model ◽  
Oral Paclitaxel

scholarly journals A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Mitchell Clark ◽  
Alexandra Kollara ◽  
Theodore J. Brown ◽  
Taymaa May
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Mouse Model ◽  
Cytoreductive Surgery ◽  
Residual Disease ◽  
Accelerated Expansion ◽  
Ovarian Cancer Cells ◽  
Orthotopic Mouse Model ◽  
The Impact

Abstract Background Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery. Methods Luciferase-expressing ID8 murine ovarian cancer cells were implanted intra-bursally and IP to C57BL/7 mice. Once disease was established by bioluminescence, 2 cycles of neoadjuvant cisplatin were administered, and animals received either ICS (removal of the injected bursa/primary tumor) or anesthesia alone. Postsurgical chemotherapy was administered on the same day as the intervention (ICS/anesthesia), or on day 7 or day 28 following the intervention. Progression was quantified serially with in vivo bioluminescence imaging. Volume of ascitic fluid volume collected at necropsy was measured. Results Animals were matched for tumor burden at stratification. There was no accelerated growth of residual tumor after interval cytoreduction compared to controls. Animals who received chemotherapy on postoperative day (POD) 7 had better disease control compared to standard-of-care POD 28. Animals who underwent surgery had less ascites at necropsy compared to those who had anesthesia alone. Conclusions In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.

scholarly journals A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin

2021 ◽  
Author(s):  
Mitchell Clark ◽  
Alexandra Kollara ◽  
Theodore Brown ◽  
Taymaa May
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Mouse Model ◽  
Cytoreductive Surgery ◽  
Residual Disease ◽  
Accelerated Expansion ◽  
Ovarian Cancer Cells ◽  
Orthotopic Mouse Model ◽  
The Impact

Abstract Background Investigate the impact of interval cytoreductive surgery (ICS) on progression in an orthotopic mouse model of ovarian cancer and the impact of chemotherapy delivered at various timelines following surgery. Methods Luciferase-expressing ID8 murine ovarian cancer cells were implanted intra-bursally and IP to C57BL/7 mice. Once disease was established by bioluminescence, 2 cycles of neoadjuvant cisplatin were administered, and animals received either ICS (removal of the injected bursa/primary tumor) or anesthesia alone. Postsurgical chemotherapy was administered on the same day as the intervention (ICS/anesthesia), or on day 7 or day 28 following the intervention. Progression was quantified serially with in vivo bioluminescence imaging. Volume of ascitic fluid volume collected at necropsy was measured. Results Animals were matched for tumor burden at stratification. There was no accelerated growth of residual tumor after interval cytoreduction compared to controls. Animals who received chemotherapy on postoperative day (POD) 7 had better disease control compared to standard-of-care POD 28. Animals who underwent surgery had less ascites at necropsy compared to those who had anesthesia alone. Conclusions In this animal model, surgical wounding with suboptimal cytoreduction after neoadjuvant chemotherapy did not cause accelerated expansion of residual disease. Surgical wounding appears to impair cisplatin activity when given at time of surgery.

scholarly journals Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (59) ◽  
pp. 100113-100127 ◽  
Author(s):  
Amanda L. Jackson ◽  
Wenchuan Sun ◽  
Joshua Kilgore ◽  
Hui Guo ◽  
Ziwei Fang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Model ◽  
Cancer Cells ◽  
Ovarian Cancer Cells ◽  
Human Ovarian Cancer ◽  
Serous Ovarian Cancer ◽  
Orthotopic Mouse Model
Sign in / Sign up

Export Citation Format

Share Document